Galectin Therapeutics (GALT) Liabilities and Shareholders Equity (2010 - 2026)

Galectin Therapeutics has reported Liabilities and Shareholders Equity for 17 years, with the latest figure at $15.8 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 65.4% year-over-year to $15.8 million; the trailing twelve-month figure through Mar 2026 stood at $63.8 million (down 23.78% YoY), and the FY2025 full-year result was $19.5 million, up 11.64% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $15.8 million, down from $19.5 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $33.6 million in Q1 2022, with the low at $9.5 million in Q1 2025.
• Average Liabilities and Shareholders Equity over 5 years is $21.3 million, with a median of $20.2 million recorded in 2023.
• Year-over-year, Liabilities and Shareholders Equity slumped 63.2% in 2025 and soared 65.4% in 2026.
• Tracing GALT's Liabilities and Shareholders Equity over 5 years: stood at $21.3 million in 2022, then surged by 32.49% to $28.2 million in 2023, then slumped by 37.96% to $17.5 million in 2024, then gained by 11.64% to $19.5 million in 2025, then fell by 19.32% to $15.8 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $15.8 million (Q1 2026), $19.5 million (Q4 2025), and $12.9 million (Q3 2025), per Business Quant data.

Peer Comparison